Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 12

finance.yahoo.com

FDA Puts Clinical Hold On Gilead’s Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings -

The FDA has placed a partial clinical hold on Gilead Sciences Inc’s (NASDAQ: GILD) studies evaluating the combination of magrolimab plus azacitidine. Due to

1486667918121312257

Mikkael A. Sekeres MD, MS

Uh-oh — FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In #MDSsm and #LEUsm — higher rates of unexpected adverse events. https://t.co/5pA38anNJk - view on twitter

More coverage: #leusm #mdssm

Read the full article here

See more from Mikkael A. Sekeres MD, MS